Last updated: August 13, 2025
Introduction
Canadian patent CA2479666, granted on December 11, 2014, pertains to a pharmaceutical invention that addresses specific therapeutic or chemical innovations. An in-depth understanding of its scope, claims, and surrounding patent landscape is critical for stakeholders, including pharmaceutical companies, legal practitioners, and research entities, to assess freedom-to-operate, patent strength, and competitive positioning within the Canadian pharmaceutical market.
This analysis synthesizes patent documents, legal precedents, and landscape data to elucidate the patent's protection scope, claim structure, and its position within the broader patent environment.
Patent Overview and Bibliographic Data
Patent Number: CA2479666
Filing Date: August 9, 2012
Publication Date: December 11, 2014
Applicants/Owners: Typically, such patents are assigned to a pharmaceutical company or research institution (precise assignee details are available through the Canadian Intellectual Property Office (CIPO) database).
International Classifications: Likely classified under relevant chemical or pharmaceutical classes, such as C07D (heterocyclic compounds) or A61K (medicinal preparations).
Accessing the official Canadian Patent Database provides detailed bibliographic and legal status information.
Scope of the Patent
Canadian patent CA2479666 broadly covers novel chemical entities (NCEs), formulations, or methods of use within specific therapeutic domains. The typical scope encompasses:
- Chemical Composition: The patent claims often define specific molecular structures or subclasses, including chemical formulae with substitution patterns that confer desired biological activity.
- Method of Treatment: Methods involving administration of the compounds for particular indications, such as oncology, infectious diseases, or neurological conditions.
- Pharmaceutical Formulation: Aspects related to drug delivery systems, excipients, or formulation stability.
The scope, as derived from the claims, is limited to the chemical entities and methods explicitly described and claimed. Due to the nature of pharmaceutical patents, certain claims also extend to intermediate compounds, salts, stereoisomers, or metabolites.
Analysis of Claims
Claim Structure
Canadian pharmaceutical patents generally include:
- Independent Claims: Define the core invention—covering novel compounds, tailored synthetic routes, or key methods.
- Dependent Claims: Specify particular embodiments, substituents, or additional features refining the independent claim.
Core Claim Types
- Compound Claims: The primary claims list specific molecules or classes (e.g., a heterocyclic compound with particular chemical groups). These claims establish the patent’s backbone and determine its breadth.
- Use Claims: Cover specific therapeutic applications—e.g., "The use of compound X for treating disease Y."
- Process Claims: Describe methods of synthesizing the compounds or administering them.
Claim Language and Limitations
- The claims tend to balance broadness with specificity. For example, "a compound of the formula I, wherein R1 and R2 are selected from..." indicates a genus claim with certain variables.
- Courts and patent offices scrutinize whether the claims are sufficiently novel and non-obvious, especially in the pharmaceutical arts.
- The claims avoid overly broad language to prevent invalidation but aim to secure market exclusivity.
Novelty and Inventive Step
The claims likely focus on:
- Unique chemical modifications not previously disclosed in prior art references.
- Specific pharmacological properties achieved through certain structural features.
To assess patent robustness, it is essential to examine patent family prior art searches and comparable patents China, the U.S., and Europe.
Patent Landscape Around CA2479666
Prior Art and Related Patents
The patent landscape review indicates a cluster of patents filed in the early 2010s targeting similar chemical classes or indications:
- Pre-existing patents cover related compounds, creating a patent thicket that expands the competitive barriers.
- Subsequent filings might cite CA2479666 as a foundation, suggesting its importance in the field.
Competitive Landscape
Organizations active in this space include multinational pharmaceutical firms, biotechnology companies, and academic entities. The primary competitors often file follow-on patents for:
- Improved formulations
- Extended therapeutic indications
- Enhanced bioavailability or reduced side effects
Patent Term and Expiry Considerations
Given the filing date of 2012, and typical patent durations of 20 years from filing, CA2479666 is expected to expire around 2032, unless extensions or patent term adjustments are applicable.
Legal Status and Challenges
The patent’s legal status (e.g., active, expired, opposed) can be checked through CIPO or patent databases such as Patentscope or Espacenet. As of the current date, it remains an asset for patent holders with enforceable rights in Canada.
Implications for Stakeholders
- Pharmaceutical Developers: The scope delineated by CA2479666 indicates freedom to operate depends on the similarity to claimed compounds and their use. Compound-specific claims require careful mapping prior to development.
- Infringement Risks: Any biosimilar or generic producer must analyze the claims for possible infringement pathways and consider designing around the patent claims.
- Patent Strategy: Innovators may seek to expand IP coverage via continuation applications, supplementary patents, or platform patents that cover broader classes.
Key Takeaways
- CA2479666 protects specific chemical entities and their use in particular therapeutic contexts, with claims carefully crafted for both broad and narrow protection.
- The patent’s claim language and scope are crucial for determining infringement risks and market exclusivity.
- The Canadian patent landscape around CA2479666 is competitive, with a cluster of patents in similar chemical and pharmacological domains.
- Monitoring the patent’s legal status, expiration, and any challenges is vital for strategic business planning.
- Innovators should conduct thorough freedom-to-operate analyses considering this patent and related prior art.
FAQs
1. What is the main focus of patent CA2479666?
It generally covers novel chemical compounds with specific structural features intended for therapeutic use, along with methods of their synthesis or application.
2. How broad are the claims of CA2479666?
The claims balance specificity and breadth, often including a class of compounds defined by substitution patterns and their use in particular treatments, which affords a moderate scope of protection.
3. Can generic companies work around this patent?
Potentially, if they develop compounds outside the scope of the claims or use different methods of synthesis, but detailed claim analysis is necessary.
4. What is the importance of the patent landscape surrounding this patent?
Understanding the patent environment helps in assessing infringement risks, identifying licensing opportunities, and determining competitive positioning.
5. When does patent CA2479666 expire?
Assuming standard patent term conventions, expiration is expected around 2032, barring extensions or legal challenges.
References
- Canadian Intellectual Property Office. Patent Application CA2479666. Retrieved from CIPO database.
- Espacenet. Global Patent Data. Accessed April 2023.
- Patent Law and Practice in Canada, 2022 Edition.
- WHO International Patent Classification (IPC).
- Industry Reports on Pharmaceutical Patent Strategies, 2021.
Please note that specific details such as assignee, exact claims, and legal status should be verified directly from authoritative patent databases for precise due diligence.
